ep: search

Creative Announces EP-630i In-Ear Stereo Headset for iPhone & iPod

Creative Technology today announced the Creative EP-630i In-Ear Stereo Headset exclusively designed for the iPhone and iPod. Available in sleek black, Creative EP-630i In-Ear Stereo Headset is perfect for call answering and music listening. With an integrated slim in-line microphone that toggles between calls and music at the simple press of a button, users never have to worry about missing a call when listening to their favourite iTunes.

Creative intros EP-630i headset for iPhone and iPod...

Creative recently introduced its newest headset, designed for use with Apple's iPhone and iPod. The EP-630i uses a pair of in-ear buds, which come with three different silicone covers to ensure users find an ideal fit. Each earbud is powered by a 9mm Neodymium magnet to deliver above average sound quality.

Suven secures European product patent

The European Patent Office (EPO) has granted Suven the product patent, EP 1581492, to its clinical candidate SUVN-502 that is valid until June 2023. EP 1581492 is an exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts. "Potential market opportunity for these indications is more than $18 billion globally. Granting of this patent to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is entering into clinical trials. Securing patent protection for our discoveries enhanced the value of our technologies and products substantially," said Venkat Jasti, CEO, Suven Life Sciences.

World's Newest, Most Powerful Laser Comes Online

deglr6328 writes "The OMEGA EP laser at the University of Rochester's Laboratory for Laser Energetics was dedicated today at the Robert L. Sproull Center for Ultra High Intensity Laser Research. The new laser, which has been in design since ~2002 will, at 1 kilojoule per 1 picosecond pulse, be the highest energy petawatt scale laser ever created by far. For a fleeting fraction of a second, it will deliver a beam of infrared light at 1054 nm that is more powerful than the total energy consumption of all human activity on the planet, to a tiny spot the size of the head of a pin. Previous petawatt scale lasers such as the one created at Lawrence Livermore labs in the late 90's (and dismantled in 1999) were capable of only several hundred joules per pulse.

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

GPC Biotech AG (Frankfurt Stock Exchange: GPC;GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum compound. The patent is entitled,

Alnylam Provides Update on "Glover" Patent

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 10, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

MARTINSRIED/MUNICH, Germany & PRINCETON, N.J. - GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum compound. The patent is entitled, “Satr

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

MARTINSRIED/MUNICH, Germany & PRINCETON, N.J. (Business Wire) -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum compound. The patent is entitled, "Satraplatin for treating resistant or refractory tumors" and covers certain uses of satraplatin related to the treatment of a cancer or tumor resistant or refractory to a taxane, including docetaxel (Taxotere(R)) and paclitaxel (Taxol(R)). The term of the patent extends up to 2025.

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

Martinsried/Munich (Germany) and Princeton, N.J., June 12, 2008 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum compound. The patent is entitled, "Satraplatin for treating resistant or refractory tumors" and covers certain uses of satraplatin related to the treatment of a cancer or tumor resistant or refractory to a taxane, including docetaxel (Taxotere®) and paclitaxel (Taxol®). The term of the patent extends up to 2025.

Applied defends SunFab thin film solar technology, does not infringe Neuchatel patent

Santa Clara, Calif.-based semiconductor, display and solar panel manufacturing equipment giant Applied Materials Inc said late Monday that it believes its SunFab thin film solar tandem junction technology does not infringe European Patent No. EP 0 871 979 issued to the University of Neuchatel (the "Neuchatel patent"), which is at issue in the Sunfilm lawsuit.

Adobe seeks International recognition for DNG

Adobe is submitting its DNG 'universal RAW' format to the International Standard's Organization (ISO), in a move aimed at increasing acceptance and usage. The format is being proposed as part of ISO's TIFF/EP (electronic photography), standard. We spoke to Adobe about the move.

Direvo Receives Broad European Patent Protection for its Protease Optimization Platform

DIREVO Cologne, Germany, June 24, 2008 - DIREVO Biotech AG, a world-wide leader in high throughput protein and strain engineering, announced today receipt of notice from the European Patent Office that the post-granting opposition period had ended without a filed opposition against Patent Grant No. EP 150411. This patent, entitled, "Process for Generating Sequence-Specific Proteases by Directed Evolution", broadly claims methods for the generation of proteases with novel, altered, or customized specificity. This further strengthens DIREVO's protease optimization platform, currently applied in two research and license agreements with Pfizer and AstraZeneca/MedImmune for the development of novel, specific proteases against multiple targets.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

ROCK BAND ADDS KILLER NINE INCH NAILS TRACKS TO DOWNLOAD CATALOG

Harmonix and MTV Games announced today the addition of Nine Inch Nails and Shinedown to the Rock Band™ Music Store catalog of downloadable content. Available July 22, the NIN three-pack includes the psychotic audio thrill ride "Burn� from the Natural Born Killers soundtrack,“Capital G� from their conceptual fifth studio release Year Zero, and“Last� from the second studio release, EP Broken. Nine Inch Nails is the Grammy winning industrial rock act founded by producer, singer, songwriter and instrumentalist, Trent Reznor more than 20 years ago with over 20 millions albums sold world wide. Each track will be available for $1.99 per track (160 Microsoft Points for Xbox 360) or $5.49 (440 Microsoft Points for Xbox 360) for the three-pack.

Nine Inch Nails songs to Rock Band this week

Harmonix and MTV Games announced today the addition of Nine Inch Nails and Shinedown to the Rock Band Music Store catalog of downloadable content. Available July 22, the NIN three-pack includes the psychotic audio thrill ride "Burn" from the Natural Born Killers soundtrack, "Capital G" from their conceptual fifth studio release Year Zero, and "Last" from the second studio release, EP Broken. Nine Inch Nails is the Grammy winning industrial rock act founded by producer, singer, songwriter and instrumentalist, Trent Reznor more than 20 years ago with over 20 millions albums sold world wide. Each track will be available for $1.99 per track (160 Microsoft Points for Xbox 360) or $5.49 (440 Microsoft Points for Xbox 360) for the three-pack.

Search took 0.01 seconds.